Tag Archives: LLY

Lilly Initiates Ph1 for New OAD

A Lilly sponsored Ph1 ClinicaTrials.gov record has been observed for LY3325656. According to the record, the compound is dosed orally and is being compared to liraglutide and in combination with sitagliptin. MOA for LY3325656 remains to be determined.

This content is for Read Less members only.
Already a member? Log in here

Lilly Increases Diabetes Manufacturing Investment in 2017

Lilly has announced intentions to invest $850M in its US operations in 2017 including $85M to expand the Trulicity device assembly operations. Additionally, Lilly announced the dedication of a $140M insulin cartridge facility.

This content is for Read Less members only.
Already a member? Log in here